Cancer Stem Cell News Volume 11.42 | Nov 16 2022

    0
    21








    2022-11-16 | CSCN 11.42


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.42 – 16 November, 2022
    TOP STORY

    Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia

    Investigators evaluated the performance of unsupervised clustering for the post-induction assessment of bulk and leukemic stem cells measurable residual disease in 155 acute myeloid leukemia patients who received intensive conventional chemotherapy treatment.
    [Clinical Cancer Research]

    Abstract
    Easy250 EasySep Magnet for rapid immune cell isolation from large-volume samples.
    PUBLICATIONSRanked by the impact factor of the journal

    Olaparib Efficacy in Patients with Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

    The authors presented exploratory analyses on the use of circulating tumor DNA testing as an additional method to identify castration-resistant prostate cancer patients with homologous recombination repair gene alterations who may be eligible for olaparib treatment.
    [Clinical Cancer Research]

    Abstract

    ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation

    Using a spontaneous model of mammary carcinoma, investigators identified bone marrow (BM) mesenchymal stem cells as the first sensors of distal cancer cells and key mediators of BM reprogramming.
    [Cancer Research]

    Abstract

    LncRNA PVT-1 Promotes Osteosarcoma Cancer Stem-Like Properties through Direct Interaction with TRIM28 and TSC2 Ubiquitination

    Scientists demonstrated that Plasmacytoma Variant Translocation-1 (PVT-1) was critical for osteosarcoma tumor-initiation potential, further elucidating the role of PVT-1 in the enhancement of cancer stem-like behaviors
    [Oncogene]

    Abstract

    DHODH Inhibition Impedes Glioma Stem Cell Proliferation, Induces DNA Damage, and Prolongs Survival in Orthotopic Glioblastoma Xenografts

    Researchers demonstrated that glioma stem cells (GSCs) lacking epidermal growth factor receptor (EGFR) amplification are exquisitely sensitive to de novo pyrimidine synthesis perturbations, while GSCs that amplify EGFR were utterly resistant.
    [Oncogene]

    Abstract

    Meis1 Supports Leukemogenesis through Stimulation of Ribosomal Biogenesis and Myc

    While HoxA9 alone immortalizes cells, cooperation with Meis1 is necessary to induce a full leukemic phenotype. The authors applied degron techniques to elucidate the leukemogenic contribution of Meis1.
    [Haematologica]

    Full Article

    Loss of miR-637 Promotes Cancer Cell Stemness via WASH/IL-8 Pathway and Serves as a Novel Prognostic Marker in Esophageal Squamous Cell Carcinoma

    Researchers identified miR-637 as a Wiskott-Aldrich syndrome protein and SCAR Homolog (WASH)-targeting miRNA. miR-637 mimic strongly attenuated the downstream IL-8 production and tumor sphere formation in esophageal cancer cells, whereas miR-637 inhibitor displayed an opposite effect.
    [Biomarker Research]

    Full Article

    CEACAM1 Is a Direct SOX10 Target and Inhibits Melanoma Immune Infiltration and Stemness

    The authors identified melanoma cell lines lacking SOX10 expression which retain their in vivo growth capabilities.
    [iScience]

    AbstractGraphical Abstract

    Single-Nucleus Transcriptomics of IDH1– and TP53-Mutant Glioma Stem Cells Displays Diversified Commitment on Invasive Cancer Progenitors

    Investigators performed single-nucleus transcriptomics of mutant and wild-type glioma samples sorted for Sox2 stem cell marker.
    [Scientific Reports]

    Full Article
    ON1104SM-Small-Molecules-Wallchart-728x90
    REVIEWS

    Inside the Stemness Engine: Mechanistic Links between Deregulated Transcription Factors and Stemness in Cancer

    Scientists review recent research findings that provide a mechanistic link between the commonly deregulated transcription factors and stemness in cancer.
    [Seminars in Cancer Biology]

    Full Article
    INDUSTRY AND POLICY NEWS

    SELLAS Life Sciences Announces Update on Phase III REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

    SELLAS Life Sciences Group, Inc. announced important updates relating to its ongoing Phase III open-label registrational clinical trial for galinpepimut-S in acute myeloid leukemia patients who have achieved complete remission following second-line salvage therapy.
    [SELLAS Life Sciences Group, Inc.]

    Press Release

    Monash BDI Researcher Wins Victorian Cancer Agency Fellowship

    Monash Biomedicine Discover Institute (BDI) researcher, Dr. Thierry Jardé has been awarded a Victorian Cancer Agency 2022 Mid-Career Research Fellowship to further his research into developing new treatment approaches against advanced bowel cancer.
    [Monash University]

    Press Release

    FEATURED EVENT

    Multispecific Immune Cell Engagers for Cancer Immunotherapy

    February 19 – 22, 2023
    Banff, Alberta, Canada

    > See All Events

    JOB OPPORTUNITIES

    Scientist – Hematological Cancers, Oncology Bioscience

    AstraZeneca – Waltham, Massachusetts, United States

    Senior Program Associate – Science in the City

    STEMCELL Technologies, Inc. – Boston, Massachusetts, United States

    PhD Studentship – Pancreatic Ductal Adenocarcinoma

    Cancer Research UK Manchester Institute – Manchester, England, United Kingdom

    University Assistants – Tumor Biology

    Johannes Kepler University of Linz – Linz, Austria

    Faculty Position – RNA and CRISPR Therapeutics

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter